ClinicalTrials.gg
CompletedNCT02665715Updated Jul 21, 2016

Can Postprandial Reactive Hypoglycaemia be Reduced in Patients After Roux-en-Y Gastric Bypass With a Low Carbohydrate Diet?

An interventional study of Low carbohydrate meals and Standard carbohydrate meals in Bariatric Surgery (Gastric Bypass), sponsored by Amirsalar Samkani. Completed at 1 site in Denmark. Open to participants aged 25 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-07-21.

Sponsored by Amirsalar Samkani · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
25 Years to 70 Years
Sex
All
01

Study summary

Roux-en-Y gastric bypass (RYGB) accelerates nutrient delivery to the small intestine causing higher peak blood glucose concentration early after meal intake. In the late postprandial period (1 1⁄2-2 h) nadir blood glucose level is lower compared with before operation. In some patients, overt postprandial hypoglycaemia develops, and is typically reported as a complication 1-5 years postoperatively, when maximal weight loss has been obtained. The pathophysiology of postprandial hypoglycaemia involves inappropriate hyper-secretion of insulin associated with exaggerated secretion of the gut hormone glucagon-like peptide-1 (GLP-1) leading to a mismatch between glucose absorption rate, insulin secretion and whole body glucose disposal. We hypothesize that lowering carbohydrate content of meals reduces postprandial glucose excursions whereby GLP-1 and insulin secretion is reduced and reactive hypoglycemia prevented.

02

Conditions studied

  • Bariatric Surgery (Gastric Bypass)

Keywords

  • Reactive hypoglycemia
  • Hyperinsulinaemia
  • Diet
  • Glucagon-like Peptide-1
  • Glucagon
  • Peptide YY
  • Ghrelin
03

In context

Hypoglycemia

654 studies on the registry are indexed under Hypoglycemia; 86 are open to participants now.

This study's enrollment of 10 is below the median of 29 across 479 interventional studies indexed under Hypoglycemia.

Browse Hypoglycemia studies →

Lead sponsor

This is the only study on the registry with Amirsalar Samkani as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • RYGB operated patients more than 12 month after operation
  • Stable in weight for at least 3 months (+/- 3 kg)
  • Plasma glucose below 3.4 mmol/L after screening with test meal (Fresubin drink) or with continuous glucose monitoring

Exclusion criteria

Exclusion Criteria:

  • Fasting plasma glucose concentration > 7mmol/L
  • Critical illness
  • Hgb \< 6.5 mM
  • Pregnancy or breastfeeding
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Low carbohydrate/Standard carbohydrate

    10 Roux-en-Y gastric bypass operated subjects are tested two days with mixed-meal tests. Each studytest day consist of both breakfast and lunch.

    Other: Low carbohydrate meals · Other: Standard carbohydrate meals

  • Experimental
    Standard carbohydrate/Low carbohydrate

    10 Roux-en-Y gastric bypass operated subjects are tested two days with mixed-meal tests. Each studytest day consist of both breakfast and lunch.

    Other: Low carbohydrate meals · Other: Standard carbohydrate meals

Interventions

  • OtherLow carbohydrate meals

    Meal macronutritional energy composition: Carbohydrate 30% Protein 30% Fat 40%

  • OtherStandard carbohydrate meals

    Meal macronutritional energy composition: Carbohydrate 55% Protein 15% Fat 30%

06

What researchers measure

Primary outcomes

  1. Nadir plasma glucose

    Between low carbohydrate meal and standard meal.

    Time frame: 0-240 min, 240-480 min

Secondary outcomes

  1. Peak plasma glucose

    Between low carbohydrate meal and standard meal.

    Time frame: 0-240 min, 240-480 min

  2. Time to nadir glucose

    Between low carbohydrate meal and standard meal.

    Time frame: 0-240 min, 240-480 min

  3. Time to peak glucose

    Between low carbohydrate meal and standard meal.

    Time frame: 0-240 min, 240-480 min

  4. Postprandial incremental glucose area

    Between low carbohydrate meal and standard meal.

    Time frame: 0-240 min, 240-480 min

  5. Postprandial decremental glucose area

    Between low carbohydrate meal and standard meal.

    Time frame: 0-240 min, 240-480 min

  6. Postprandial incremental insulin area

    Between low carbohydrate meal and standard meal.

    Time frame: 0-240 min, 240-480 min

  7. Postprandial incremental GLP-1 area

    Between low carbohydrate meal and standard meal.

    Time frame: 0-240 min, 240-480 min

  8. Time below basline glucose concentrations

    Between low carbohydrate meal and standard meal.

    Time frame: 0-480 min

  9. Glycemic excursions

    Between low carbohydrate meal and standard meal.

    Time frame: 0-480 min

07

Study locations

1 site
  • Endocrinology Research Center, Hvidovre University Hospital
    Hvidovre, Copenhagen 2650, Denmark
08

References and documents

Publications

  • Kandel D, Bojsen-Moller KN, Svane MS, Samkani A, Astrup A, Holst JJ, Madsbad S, Krarup T. Mechanisms of action of a carbohydrate-reduced, high-protein diet in reducing the risk of postprandial hypoglycemia after Roux-en-Y gastric bypass surgery. Am J Clin Nutr. 2019 Aug 1;110(2):296-304. doi: 10.1093/ajcn/nqy310. PubMed 30624666 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2015, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2016
First posted
Jan 28, 2016
Start
Aug 2015
Primary completionActual
Jun 2016
CompletionActual
Jun 2016
Last update
Jul 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02665715
Lead sponsor
Amirsalar Samkani
Responsible party
Amirsalar Samkani (PhD-Student, Bispebjerg Hospital) — Sponsor-investigator
First posted
Jan 28, 2016
Start date
Aug 2015
Primary completion
Jun 2016
Completion
Jun 2016
Last update
Jul 21, 2016

Study contacts

Kirstine Bojsen-Moller, MD, Postdoc
principal investigator · Hvidovre University Hospital
Sten Madsbad, MD, Prof
principal investigator · Hvidovre University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion